7. Sell Side M&A Advice
b'
In 2005, Vamsi started his own company focused on data compliance for the pharmaceutical industry. His company provided technology to support clinical trials to the FDA. \\u201cI like to build companies, but I also like change. [After five years], I thought about selling the company and rolling it up into a publicly listed company.\\u201d He sold it in 2010 and moved to India to pursue new opportunities. While the sale was smooth, there were numerous post-sale challenges. \\u201cThey basically ran down the company within 18 months.\\u201d
\\xa0
0:00 \\u2013 4:03 Vamsi\\u2019s background at Deloitte, Pfizer, Merrill Lynch
4:04 \\u2013 6:27 Acquiring Clinovo (how found and why chose over others)
6:28 \\u2013 9:24 Due diligence process as a buyer
9:25 \\u2013 11:24 Issues that came up during diligence process
11:25 \\u2013 13:39 Working with the investment banker
13:40 \\u2013 14:19 Interaction with seller prior to closing
14:20 \\u2013 19:19 Challenges with integration
19:20 \\u2013 21:55 Lessons learned and post-closing challenges
21:56 \\u2013 23:05 Lessons from the sell side
23:06 \\u2013 23:38 What\\u2019s on the horizon
\\xa0
M&A Science by Kison Patel (kison@dealroom.net)
DealRoom: Data Science and AI for M&A (www.dealroom.net)
'